Pharma takes major decisions to focus on production of coronavirus vaccine


Pfizer said on Friday it is in talks to shift more of its medicine production to outside contractors as it prepares for large-scale production of an experimental vaccine to prevent COVID-19, should it prove safe and effective. The U.S. drugmaker is tapping its network of around 200 outside contractors, which includes Catalent, Lonza Group, and Thermo Fisher Scientific, to play a bigger role in producing some of its existing medicines, Mike McDermott, president of global supply at Pfizer, told Reuters in an interview.